At Endometriosis Surgical Specialists International (ESSI), we are committed to advancing pain management strategies, especially during the most challenging moments: post-surgical recovery and acute flare-ups. A promising new option now available to our patients is FDA-approved Journavx (suzetrigine). This first oral sodium-channel blocker delivers targeted, long-lasting pain relief without the need for injections, patches, or high-dose opioids.
How Journavx Works: Local Anesthetic Power, Systemic Reach
Journavx belongs to a new class of precision analgesics that function like lidocaine, numbing pain at the nerve level, but in a convenient oral form.
- 8 sodium-channel blocker: Journavx selectively inhibits NaV1.8 pain channels, key conduits for pain signal transmission. This precision targeting minimizes the systemic effects common with traditional medications.
- Opioid-sparing relief: By blocking pain signals before they reach the brain, Journavx helps reduce reliance on opioids and NSAIDs, lowering the risk of side effects and dependence.
- Extended pain control: A single dose may provide up to 48 hours of relief, making it ideally suited to the intense post-operative pain window.
How ESSI Uses Journavx in Endometriosis Care
We have integrated Journavx into our acute pain protocols at ESSI in three key ways:
- Post-surgical support: Patients undergoing laparoscopic or robotic excision at ESSI receive Journavx immediately after surgery. This helps reduce discomfort, decrease opioid use, and promote faster recovery.
- Acute flare management: Journavx is also used to treat sudden pain flares. As an oral medication, it eliminates the need for injections or urgent visits, making it a powerful at-home option.
- Personalized treatment planning: Our pain specialists tailor Journavx dosing to each patient’s specific needs, ensuring effective relief while carefully monitoring for any potential side effects.
ESSI’s Commitment to Innovation and Patient Experience
At ESSI, we believe that clinical excellence and innovation must go hand-in-hand. We continuously evaluate new therapies based on real-world patient outcomes and integrate them into practice when they offer meaningful improvements. Our approach ensures that research is not just an abstract concept, but a lived experience that improves recovery, autonomy, and long-term quality of life for every patient we serve.
Conclusion
Journavx represents a significant advancement for endometriosis-related pain care. Its targeted mechanism, extended relief, and ease of use make it a valuable tool for both post-surgical recovery and flare-up management. At ESSI, we are proud to lead the way in offering next-generation therapies that elevate the standard of care and put the patient experience first.
Journavx is currently available in the United States at over 33,000 national and regional retail pharmacies—but as of June 20, 2025, it has not yet been launched or approved for use in any European country.
Physician Perspectives on Journavx
“I am glad to have another option for pain management for patients with endometriosis and look forward to using it with the right candidates.”
— Dr. Mallory Stuparich, Endometriosis Surgical Specialists International
“Journavx represents a new frontier in treating post-operative and chronic flare pain. For patients who have exhausted traditional options, this provides a more targeted and better-tolerated path forward.”
— Dr. Andrea Vidali, Endometriosis Surgical Specialists International
“In our practice, we prioritize precision medicine. Journavx aligns with that mission—it’s promising to see a drug designed to selectively target pain at the neural level without the drawbacks of systemic opioids.”
— Dr. Madhu Bagaria, Endometriosis Surgical Specialists International
“Siento una profunda responsabilidad y compromiso de brindar a nuestras pacientes en ESSI las innovaciones más recientes en el tratamiento de la endometriosis. Para mí, ofrecer una atención médica de vanguardia no es solo una prioridad, es una misión.”
— Dr. Osbert Fernandez, Endometriosis Surgical Specialists International
